1BAYN Stock Overview
Operates as a life science company worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Bayer Aktiengesellschaft Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €19.54 |
| 52 Week High | €36.01 |
| 52 Week Low | €19.41 |
| Beta | 1 |
| 11 Month Change | -24.18% |
| 3 Month Change | -29.97% |
| 1 Year Change | -40.75% |
| 33 Year Change | -58.86% |
| 5 Year Change | -71.57% |
| Change since IPO | 40.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1BAYN | IT Pharmaceuticals | IT Market | |
|---|---|---|---|
| 7D | -5.0% | -3.0% | -0.7% |
| 1Y | -40.7% | 4.3% | 12.7% |
Return vs Industry: 1BAYN underperformed the Italian Pharmaceuticals industry which returned 4.3% over the past year.
Return vs Market: 1BAYN underperformed the Italian Market which returned 12.7% over the past year.
Price Volatility
| 1BAYN volatility | |
|---|---|
| 1BAYN Average Weekly Movement | 6.2% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 4.2% |
| 10% most volatile stocks in IT Market | 7.5% |
| 10% least volatile stocks in IT Market | 2.4% |
Stable Share Price: 1BAYN's share price has been volatile over the past 3 months compared to the Italian market.
Volatility Over Time: 1BAYN's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of Italian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1863 | 94,245 | Bill Anderson | www.bayer.com |
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy.
Bayer Aktiengesellschaft Fundamentals Summary
| 1BAYN fundamental statistics | |
|---|---|
| Market cap | €19.20b |
| Earnings (TTM) | -€880.00m |
| Revenue (TTM) | €46.74b |
0.4x
P/S Ratio-21.8x
P/E RatioIs 1BAYN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1BAYN income statement (TTM) | |
|---|---|
| Revenue | €46.74b |
| Cost of Revenue | €20.03b |
| Gross Profit | €26.71b |
| Other Expenses | €27.59b |
| Earnings | -€880.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 05, 2025
| Earnings per share (EPS) | -0.90 |
| Gross Margin | 57.15% |
| Net Profit Margin | -1.88% |
| Debt/Equity Ratio | 134.1% |
How did 1BAYN perform over the long term?
See historical performance and comparison